Cabaletta Bio (CABA) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Cabaletta Bio, Inc. (CABA) relies on the development of precision therapies that enable significant pricing power due to extremely high demand for treatment. CARTA technology ensures the selective depletion of pathogenic B-cells, avoiding systemic suppression of the body's immune defenses. The implementation of cloud-based quality control and automated engineering systems fixes the metric at 0.00. The price history on the separate_ev_ebitda chart is presented below.
cabalettabio.com - analytical breakdowns and key metrics (CABA)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity Cabaletta Bio, Inc.|CABA - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Cabaletta Bio|CABA - Company Cumulative Debt|Debts to Book Capitalization Cabaletta Bio Inc|CABA - Company Long-Term Liabilities|Company Short-Term Debts Cabaletta Bio, Inc.|Quick Ratio cabalettabio.com
- business earnings and investment ratios data:
CABA - Company Net Income|Projected Future Earnings Cabaletta Bio, Inc.|CABA - P/E Multiple|Future Price to Earnings Cabaletta Bio, Inc.|CABA - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Cabaletta Bio Inc|CABA - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Cabaletta Bio, Inc.|CABA - Earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months cabalettabio.com|CABA - Net earnings per one share growth for the current year|Earnings growth forecast for next year Cabaletta Bio, Inc.
Initial company analysis:Cabaletta Bio, Inc CABA
Cabaletta Bio, Inc. (CABA) strives for technological leadership in the therapy of autoimmune diseases, making its valuation dependent on future earnings. The 0.00 metric compares the total enterprise value of the business with its operating income before taxes, depreciation, and amortization. This ratio determines the market revaluation of assets relative to actual production efficiency. The EV/EBITDA trend over a given time interval allows for an assessment of the company's investment attractiveness compared to industry peers.
Competitors of Cabaletta Bio, Inc. (CABA)
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple Grifols Biemat|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies (ADPT)|celldex.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|BioCryst Pharmaceuticals, Inc. (BCRX) - Company Value to EBITDA|Vera Pharma - EV/EBITDA Multiple|Dianthus Corp (DNTH) - Enterprise Value to EBITDA Ratio|PHVS: EV/EBITDA Multiple|AbCellera (ABCL) - EV/EBITDA Multiple|TRML (Tourmaline Bio) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PGEN|EV/EBITDA Multiple PHAR|EV/EBITDA Multiple Nektar Corp (NKTR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Upstream Bio Inc UPB|zenasbio.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Immunome - EV/EBITDA Multiple|Company Value to EBITDA Gossamer Bio Inc|KALV (KalVista Pharmaceuticals Inc) - Enterprise Value to EBITDA Ratio|SEPN: Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio PVLA|SVRA (savarapharma.com) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple RIGL|EV/EBITDA Multiple AnaptysBio Inc (ANAB)|Astria Pharma - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ENGN|RAPT Therapeutics - EV/EBITDA Multiple|JBIO: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACRS: EV/EBITDA Multiple|KYTX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tiziana Life Sciences PLC|Company Value to EBITDA Ventyx Biosciences, Inc VTYX|Enterprise Value to EBITDA Ratio THTX (Theratechnologies Inc.)|AVTX (avalotx.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ELDN (Eledon Pharmaceuticals, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Agenus, Inc. (AGEN)|CLYM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ZURA (zurabio.com) - Enterprise Value to Operating Income Before Depreciation|ATYR: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Adagene Inc.|Enterprise Value to EBITDA Ratio IMA|Shattuck Therapeutics (STTK) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple EQ|Enterprise Value to EBITDA Ratio connectbiopharm.com CNTB|EV/EBITDA Multiple IMUX (Immunic)|EV/EBITDA Multiple Atara Biotherapeutics, Inc. ATRA|InflaRx GmbH - EV/EBITDA Multiple|XFOR: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACET: EV/EBITDA Multiple|Celularity (CELU) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization INmune Bio, Inc.|barinthusbio.com - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple KZR|SABS (SAB Biotherapeutics Inc.) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple AKTX (Akari Therapeutics plc)|EV/EBITDA Multiple Enlivex Therapeutics Ltd ENLV|QTTB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation GOVX (geovax.com)|Edesa Biotech (EDSA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio iBio Inc|CARM (Carisma Therapeutics Inc) - EV/EBITDA Multiple|EV/EBITDA Multiple XTL Bio|Enterprise Value to EBITDA Ratio BOLT (Bolt Biotherapeutics)|HCWB (hcwbiologics.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple APVO (Aptevo Therapeutics Inc.)|Total Company Value to Operating Income Before Depreciation Ratio aimimmuno.com (AIM)|ADTX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GRI Bio Corporation (GRI) - Enterprise Value to EBITDA Ratio|XORTX Therapeutics Inc. (XRTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio reshapelifesciences.com|Enterprise Value to EBITDA Ratio REVB|EV/EBITDA Multiple Indaptus Therapeutics Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Scinai (SCNI)|calcimedica.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AFMD (Affimed N.V.)|Allakos Inc (ALLK) - Company Value to EBITDA|HOOKIPA - EV/EBITDA Multiple|IGM Biosciences, Inc. (IGMS) - Enterprise Value to EBITDA Ratio|ITOS: EV/EBITDA Multiple|Ocean Biomedical Corp (OCEA) - EV/EBITDA Multiple|TCBP (TC Biopharm) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization THRD
